4873 related articles for article (PubMed ID: 25079552)
1. Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network
Nature; 2014 Jul; 511(7511):543-50. PubMed ID: 25079552
[TBL] [Abstract][Full Text] [Related]
2. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
3. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.
Zhao J; Sun Y; Huang Y; Song F; Huang Z; Bao Y; Zuo J; Saffen D; Shao Z; Liu W; Wang Y
Sci Rep; 2017 Jan; 7():40488. PubMed ID: 28091594
[TBL] [Abstract][Full Text] [Related]
5. Mutation Profile of Resected
Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
[TBL] [Abstract][Full Text] [Related]
6. The transcriptional landscape and mutational profile of lung adenocarcinoma.
Seo JS; Ju YS; Lee WC; Shin JY; Lee JK; Bleazard T; Lee J; Jung YJ; Kim JO; Shin JY; Yu SB; Kim J; Lee ER; Kang CH; Park IK; Rhee H; Lee SH; Kim JI; Kang JH; Kim YT
Genome Res; 2012 Nov; 22(11):2109-19. PubMed ID: 22975805
[TBL] [Abstract][Full Text] [Related]
7. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
8. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach.
Li R; Wang H; Bekele BN; Yin Z; Caraway NP; Katz RL; Stass SA; Jiang F
Oncogene; 2006 Apr; 25(18):2628-35. PubMed ID: 16369491
[TBL] [Abstract][Full Text] [Related]
9. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.
Chitale D; Gong Y; Taylor BS; Broderick S; Brennan C; Somwar R; Golas B; Wang L; Motoi N; Szoke J; Reinersman JM; Major J; Sander C; Seshan VE; Zakowski MF; Rusch V; Pao W; Gerald W; Ladanyi M
Oncogene; 2009 Aug; 28(31):2773-83. PubMed ID: 19525976
[TBL] [Abstract][Full Text] [Related]
10. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
[TBL] [Abstract][Full Text] [Related]
11. Gene aberrations for precision medicine against lung adenocarcinoma.
Saito M; Shiraishi K; Kunitoh H; Takenoshita S; Yokota J; Kohno T
Cancer Sci; 2016 Jun; 107(6):713-20. PubMed ID: 27027665
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
14. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
15. Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
Zhang L; Li S; Choi YL; Lee J; Gong Z; Liu X; Pei Y; Jiang A; Ye M; Mao M; Zhang X; Kim J; Chen R
Lung Cancer; 2017 Jul; 109():21-27. PubMed ID: 28577945
[TBL] [Abstract][Full Text] [Related]
16. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
17. Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma.
Paliogiannis P; Attene F; Cossu A; Defraia E; Porcu G; Carta A; Sotgiu MI; Pazzola A; Cordero L; Capelli F; Fadda GM; Ortu S; Sotgiu G; Palomba G; Sini MC; Palmieri G; Colombino M
Mol Med Rep; 2015 Jul; 12(1):187-91. PubMed ID: 25683726
[TBL] [Abstract][Full Text] [Related]
18. Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.
Planck M; Edlund K; Botling J; Micke P; Isaksson S; Staaf J
PLoS One; 2013; 8(10):e78614. PubMed ID: 24205279
[TBL] [Abstract][Full Text] [Related]
19. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
Sholl LM; Yeap BY; Iafrate AJ; Holmes-Tisch AJ; Chou YP; Wu MT; Goan YG; Su L; Benedettini E; Yu J; Loda M; Jänne PA; Christiani DC; Chirieac LR
Cancer Res; 2009 Nov; 69(21):8341-8. PubMed ID: 19826035
[TBL] [Abstract][Full Text] [Related]
20. EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.
Chen HY; Liu CH; Chang YH; Yu SL; Ho BC; Hsu CP; Yang TY; Chen KC; Hsu KH; Tseng JS; Hsia JY; Chuang CY; Chang CS; Li YC; Li KC; Chang GC; Yang PC
Oncotarget; 2016 Feb; 7(8):9017-25. PubMed ID: 26824984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
